MedTrace Logo

Customized Choice of Oral P2Y12 Receptor Blocker

NCT01477775 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4000

Last updated 2014-09-03

No results posted yet for this study

Summary

A subset of patients recruited in the main MATRIX study will be randomized after intervention but before discharge to standard of care (the treating physician will decide which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach based on an algorithm which integrates phenotypic information, including but not limited to residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.

Conditions

  • Acute Coronary Syndrome
  • Coronary Angioplasty

Interventions

DRUG

Oral P2Y12 receptor blocker

Free choice among clopidogrel, prasugrel or ticagrelor

DRUG

Customized choice for the oral P2Y12 receptor blocker

one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.

Sponsors & Collaborators

  • Eustrategy

    collaborator OTHER

  • Italian Society of Invasive Cardiology

    lead OTHER

Principal Investigators

  • Marco Valgimigli, MD, PhD · University Hospital of Ferrara

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-12-31
Completion
2015-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01477775 on ClinicalTrials.gov